报价延迟最少15分钟:2025/07/21 08:30 EDT
盘前时段
|
||||
|
1.345 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.3
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.41/-0.33
|
|
企业价值
47.76M
|
| 资产负债 |
|
每股账面净值
0.36
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
43.00K
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 08:30 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. |
